SNDX Syndax Pharmaceuticals, Inc.

12.92
-0.97  -7%
Previous Close 13.89
Open 12.75
Price To book 3.49
Market Cap 235.85M
Shares 18,255,000
Volume 1,965,328
Short Ratio 2.80
Av. Daily Volume 206,768

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 part of Phase 1b/2 trial recently initiated - as noted March 2, 2017.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 trial to advance to second stage of trial - noted May 16, 2017. Poster presentation at ASCO June 3, 2017.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC)
Phase 3 PFS data due by the end of 2017.
E2112
HR+, HER2- breast cancer

Latest News

  1. Syndax Prices Public Offering of Common Stock
  2. Syndax Announces Proposed Public Offering of Common Stock
  3. Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
  4. Why Syndax Shares Are Rallying
  5. Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies
  6. Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference
  7. Edited Transcript of SNDX earnings conference call or presentation 8-May-17 8:30pm GMT
  8. Syndax reports 1Q loss
  9. Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update
  10. Investor Network: Syndax Pharmaceuticals Inc. to Host Earnings Call
  11. Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017
  12. Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer
  13. Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
  14. Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
  15. Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
  16. Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  17. Edited Transcript of SNDX earnings conference call or presentation 2-Mar-17 9:30pm GMT
  18. Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update
  19. Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?